Accelerated Partial Breast Irradiation Demonstrates Efficacy in Low-Risk Breast Cancer
October 25th 2015Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.
Read More
Novel Epigenetic Therapy Shows Clinical Activity in Hematologic Malignancies
July 2nd 2014Preliminary evidence supports the use of bromodomain inhibitors in hematologic malignancies, including acute leukemia (mainly acute myelogenous leukemia) and other hematological malignancies, including diffuse large B-cell lymphoma and multiple myeloma.
Read More
PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer
December 13th 2013PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.
Read More
Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery
December 12th 2013Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.
Read More
Unique Considerations With TKIs for Chronic Myelogenous Leukemia
October 25th 2013At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia
Read More
Novel B-Cell Receptor Signaling Inhibitors Show Promise
October 23rd 2013Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.
Read More
Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer
October 3rd 2013Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA-1 trial.
Read More
Novel ALK Inhibitor Shows Promise Against Brain Metastasis in NSCLC
September 30th 2013The first-in-human phase I/II dose-finding study of a novel ALK/EGFR inhibitor called AP26113 demonstrated promising results in both crizotinib-resistant and crizotinib-naïve patients with non-small cell lung cancer.
Read More
BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus
September 30th 2013Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.
Read More
PD-L1 Inhibitor Delivers Rapid, Durable Responses in Advanced NSCLC
September 29th 2013A phase I study has shown remarkable and durable responses with the engineered monoclonal antibody MPDL3280A in metastatic non-small cell lung cancer, including tumors with squamous and adenocarcinoma histology.
Read More
Surveillance Following Orchiectomy Most Costly Option for Stage I Testicular Seminoma
May 2nd 2013A cost analysis found that para-aortic radiotherapy, dogleg radiotherapy, and 1 cycle of carboplatin are cost-effective strategies for the management of stage I testicular seminoma post-orchiectomy compared with surveillance.
Read More
Abiraterone Continues to Show Survival Benefit in Updated Interim Analysis
February 15th 2013An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.
Read More